Eli Lilly and Company (NYSE:LLY) Position Increased by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,723 shares of the company’s stock after buying an additional 276 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Eli Lilly and Company were worth $7,898,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Capital Planning LLC bought a new position in shares of Eli Lilly and Company during the first quarter worth about $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $6,916,000. M&G Plc bought a new position in Eli Lilly and Company in the 1st quarter worth about $8,896,000. IPG Investment Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $351,000. Finally, HighPoint Advisor Group LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $9,878,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 442,229 shares of company stock worth $410,002,456. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.7 %

Eli Lilly and Company stock opened at $921.72 on Friday. The firm has a market cap of $876.01 billion, a price-to-earnings ratio of 135.75, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The firm’s 50 day moving average price is $895.06 and its two-hundred day moving average price is $837.89. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a dividend of $1.30 per share. The ex-dividend date was Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.56%. Eli Lilly and Company’s payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. Guggenheim increased their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their target price for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.